BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34118469)

  • 1. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
    Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
    Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
    Redondo S; Esquirol A; Novelli S; Caballero AC; Garrido A; Oñate G; López J; Moreno C; Saavedra SD; Granell M; Briones J; Sierra J; Martino R; García-Cadenas I
    Transplant Cell Ther; 2022 Jan; 28(1):43.e1-43.e5. PubMed ID: 34757054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
    Kaurinovic M; Delli K; Jonk AE; Biswana A; Hazenberg CLE; Choi G; de Groot MR; Morsink LM; Vissink A; Bellido M
    Clin Oral Investig; 2022 May; 26(5):4209-4216. PubMed ID: 35169886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of ruxolitinib in the salvage treatment of chronic graft versus-host disease].
    Ji YP; Tang BL; Zhu XY; Liu HL; Song KD; Wan X; Yao W; Sun GY; Wang J; Sun ZM
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(16):1235-1239. PubMed ID: 32344495
    [No Abstract]   [Full Text] [Related]  

  • 11. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
    Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
    Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
    Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
    Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
    Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
    Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.